Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Novasep","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Novasep"}]

Novasep

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

Details:

With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.

Lead Product(s): LYS-GM101

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Lysogene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 25, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY